SUBSCRIBE
SUBSCRIBE
News   Policy

Novartis AG Sees $590 Million Charge Because of Drug Trial Stoppages for Antifungal Agent Mycograb as Well as Zalbin

October 5, 2010 | 
1 min read
Bloomberg -- Novartis AG is stopping development of two experimental medicines, a decision that will result in charges of about $590 million in charges in the third quarter.
Legal Europe
Novartis
MORE ON THIS TOPIC
Abstract creative financial graph with finger clicks on a digital tablet on background, forex and investment concept.
Legal
Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Drug pricing
Trump Administration Reaches Pricing Agreements With 9 More Drugmakers
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Policy
Disc Shares Slip Amid Report FDA’s Prasad Is Skeptical of Bitopertin’s Efficacy
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
FDA
FDA Policy Tracker: 2025 Was a Year of Change
December 22, 2025
 · 
13 min read
 · 
Heather McKenzie